+Follow
嗣舒
No personal profile
7
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
嗣舒
10-12
Share your opinion about this news…
How To Invest: Biotechs Can Make Huge Gains But Have Unique Risks
嗣舒
05-22
Share your opinion about this news…
司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4115205500438802","uuid":"4115205500438802","gmtCreate":1652106048121,"gmtModify":1697841292118,"name":"嗣舒","pinyin":"sssishu","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":7,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.25","exceedPercentage":"93.57%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.11","exceedPercentage":"93.83%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.25","exceedPercentage":"93.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":4,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":359181164835000,"gmtCreate":1728698717312,"gmtModify":1728698869527,"author":{"id":"4115205500438802","authorId":"4115205500438802","name":"嗣舒","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4115205500438802","idStr":"4115205500438802"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/359181164835000","repostId":"2474093237","repostType":2,"repost":{"id":"2474093237","pubTimestamp":1728648005,"share":"https://ttm.financial/m/news/2474093237?lang=&edition=fundamental","pubTime":"2024-10-11 20:00","market":"sg","language":"en","title":"How To Invest: Biotechs Can Make Huge Gains But Have Unique Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2474093237","media":"Blockhead","summary":"In some cases, biotechs go public without having even a single product on the market.","content":"<html><body><div>\n<p>There are plenty of great growth stocks within IBD's biotechnology industry group. Investors have heard legendary stories of stocks like Genentech running up 300% in the 1980s or <strong>Amgen</strong> (AMGN) rocketing 600% in the early 1990s.</p>\n<p>When the gains look this good, what is keeping this from being the No. 1 industry group in every market cycle? Trouble is, biotech stocks have some unique risks that make them particularly volatile and often harder to trade.</p>\n<span>\n<span>\n<span jw-video-key=\"FczkHzgb\" vid-authors=\"RACHEL FOX\" vid-cat=\"Investor's Corner\" vid-date=\"09/26/2024\" vid-date-tmsp=\"1727347777\" vid-dom-id=\"9413049-67091849b73b3\" vid-id=\"9413049\" vid-image=\"https://www.investors.com/wp-content/uploads/2024/09/FczkHzgb-640x360.jpg\" vid-name=\"How To Buy Stocks: IBD's Four Pillars Of Investing\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/FczkHzgb.m3u8\" vid-width=\"100\">\n<span>↑</span>\n<span>X</span>\n<span>\n<span></span>\n<div>\n<div>\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n</div>\n<div>\nSee All Videos\n</div>\n</div>\n</span>\n<span>\n<span>NOW PLAYING</span>\n<span>How To Buy Stocks: IBD's Four Pillars Of Investing</span>\n</span>\n</span>\n</span>\n</span>\n<p>In some cases, biotechs go public without having even a single product on the market, making them quite speculative investments.</p>\n<h2>The Risks Of Biotechs</h2>\n<p>The biotech industry is flush with stocks on the cutting edge of science whose aim is to eradicate disease, increase life expectancy and vastly improve quality of life. The time and resources that it takes to bring these drugs and treatments to fruition means most companies are only producing one or two drugs at a time. All your eggs are in one or two baskets.</p>\n<p>If something goes wrong with that product, look out. The floor collapses from underneath and the stock's price plummets, sometimes never to recover. Worst of all, you can't prepare for a bad drug trial or an FDA rejection. They don't occur on a schedule like earnings reports do.</p>\n<p>It's worth mentioning that this type of risk extends to others in the medical sector, such as the ethical drugs group, which is also subject to regulatory approval and the risks of drug trials.</p>\n<h2>How To Trade Biotech Stocks</h2>\n<p>There are a few things that investors can do to mitigate the risk of trading biotech stocks.</p>\n<p>One way is to go with exchange traded funds, which bundle dozens of stocks in the industry and can mitigate the risk of a single stock having a meltdown.</p>\n<p>Your two most liquid options are the SPDR S&P Biotech ETF (XBI) and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotech ETF (IBB). Investors with high conviction can even trade the double-weighted ProShares Ultra Nasdaq Biotech ETF (BIB) or triple-weighted Direxion S&P Biotech Bull (LABU).</p>\n<p>Be warned, the double- and triple-leveraged ETFs can be backbreakers, exacerbating your losses if the industry makes a steep downturn.</p>\n<p>A second tip: smart stock selection. Start with success and choose from leading stocks with a new or revolutionary product. The biggest winners in any industry are the ones who are changing the game, and the same is true of biotechs. Focus on companies with strong sales growth.</p>\n<p>Amgen changed patient care in chemotherapy. Syntex was the first company to submit a patent for a birth control pill. <strong>Moderna</strong> (MRNA) and <strong>BioNTech</strong> (BNTX) were huge winners in 2020 and 2021 because of Covid-19 vaccines.</p>\n<p>Another tip on stock selection: Avoid stocks once they reach Phase 3 trials. Wall Street prefers stocks with positive Phase 2 data. In Phase 3, as the sample size increases, so does the chance of encountering dangerous side effects. Larger sample sizes can also reveal a drop in statistically meaningful positive responses.</p>\n<h2>Novo Nordisk & HilleVax Lessons</h2>\n<p>Last July, <strong>Novo Nordisk</strong> (NVO) stock was acting just fine. Then the Netherlands government decided to not cover the company's Wegovy weight-loss drug under the country's basic insurance plan. The stock sold off for two days, sending it below the 50-day moving average.</p>\n<p>On Sept. 20, results from a trial of an experimental obesity pill were disappointing. The stock fell 5.5% and continued to trend lower.</p>\n<p><strong>HilleVax</strong> (HLVX) is a small-cap biotech developing novel vaccines. The stock was forming a base this year until some bad news came out on July 8. Its experimental norovirus vaccine failed trials. The stock plummeted to $1.64, falling nearly 90% from the day prior. The stock remains around 1.75 a share.</p>\n<p><strong>YOU MAY ALSO LIKE:</strong></p>\n<p>The Four Pillars Of The IBD Methodology</p>\n<p>Risk Management In The Stock Market: How Much Money To Invest</p>\n<p>IBD Live: Learn And Analyze Growth Stocks With The Pros</p>\n<p>Get Free IBD Newsletters: Market Prep | Tech Report | How To Invest</p>\n</div></body></html>","source":"investor_business_daily_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How To Invest: Biotechs Can Make Huge Gains But Have Unique Risks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow To Invest: Biotechs Can Make Huge Gains But Have Unique Risks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 20:00 GMT+8 <a href=https://www.investors.com/how-to-invest/investors-corner/how-to-invest-biotech-stock-risks/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There are plenty of great growth stocks within IBD's biotechnology industry group. Investors have heard legendary stories of stocks like Genentech running up 300% in the 1980s or Amgen (AMGN) ...</p>\n\n<a href=\"https://www.investors.com/how-to-invest/investors-corner/how-to-invest-biotech-stock-risks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://www.investors.com/wp-content/uploads/2017/11/stock-biotech-05-adobe-150x150.jpg","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","IBB":"生物科技指数ETF-iShares Nasdaq","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4501":"段永平概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","NVO.AU":"NOVO RESOURCES CORP-CDI","LABU":"三倍做多标普生物-Direxion","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","AMGN":"安进","BK7104":"黄金","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4551":"寇图资本持仓","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BNTX":"BioNTech SE","BK4581":"高盛持仓","FDN":"First Trust Dow Jones Internet I","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","HLVX":"HilleVax, Inc.","MRNA":"Moderna, Inc.","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BIB":"Ultra纳斯达克生物科","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","BK4548":"巴美列捷福持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4532":"文艺复兴科技持仓","XBI":"SPDR S&P Biotech ETF","NVO":"诺和诺德"},"source_url":"https://www.investors.com/how-to-invest/investors-corner/how-to-invest-biotech-stock-risks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2474093237","content_text":"There are plenty of great growth stocks within IBD's biotechnology industry group. Investors have heard legendary stories of stocks like Genentech running up 300% in the 1980s or Amgen (AMGN) rocketing 600% in the early 1990s.\nWhen the gains look this good, what is keeping this from being the No. 1 industry group in every market cycle? Trouble is, biotech stocks have some unique risks that make them particularly volatile and often harder to trade.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n\n\n\n\nIn some cases, biotechs go public without having even a single product on the market, making them quite speculative investments.\nThe Risks Of Biotechs\nThe biotech industry is flush with stocks on the cutting edge of science whose aim is to eradicate disease, increase life expectancy and vastly improve quality of life. The time and resources that it takes to bring these drugs and treatments to fruition means most companies are only producing one or two drugs at a time. All your eggs are in one or two baskets.\nIf something goes wrong with that product, look out. The floor collapses from underneath and the stock's price plummets, sometimes never to recover. Worst of all, you can't prepare for a bad drug trial or an FDA rejection. They don't occur on a schedule like earnings reports do.\nIt's worth mentioning that this type of risk extends to others in the medical sector, such as the ethical drugs group, which is also subject to regulatory approval and the risks of drug trials.\nHow To Trade Biotech Stocks\nThere are a few things that investors can do to mitigate the risk of trading biotech stocks.\nOne way is to go with exchange traded funds, which bundle dozens of stocks in the industry and can mitigate the risk of a single stock having a meltdown.\nYour two most liquid options are the SPDR S&P Biotech ETF (XBI) and the iShares Biotech ETF (IBB). Investors with high conviction can even trade the double-weighted ProShares Ultra Nasdaq Biotech ETF (BIB) or triple-weighted Direxion S&P Biotech Bull (LABU).\nBe warned, the double- and triple-leveraged ETFs can be backbreakers, exacerbating your losses if the industry makes a steep downturn.\nA second tip: smart stock selection. Start with success and choose from leading stocks with a new or revolutionary product. The biggest winners in any industry are the ones who are changing the game, and the same is true of biotechs. Focus on companies with strong sales growth.\nAmgen changed patient care in chemotherapy. Syntex was the first company to submit a patent for a birth control pill. Moderna (MRNA) and BioNTech (BNTX) were huge winners in 2020 and 2021 because of Covid-19 vaccines.\nAnother tip on stock selection: Avoid stocks once they reach Phase 3 trials. Wall Street prefers stocks with positive Phase 2 data. In Phase 3, as the sample size increases, so does the chance of encountering dangerous side effects. Larger sample sizes can also reveal a drop in statistically meaningful positive responses.\nNovo Nordisk & HilleVax Lessons\nLast July, Novo Nordisk (NVO) stock was acting just fine. Then the Netherlands government decided to not cover the company's Wegovy weight-loss drug under the country's basic insurance plan. The stock sold off for two days, sending it below the 50-day moving average.\nOn Sept. 20, results from a trial of an experimental obesity pill were disappointing. The stock fell 5.5% and continued to trend lower.\nHilleVax (HLVX) is a small-cap biotech developing novel vaccines. The stock was forming a base this year until some bad news came out on July 8. Its experimental norovirus vaccine failed trials. The stock plummeted to $1.64, falling nearly 90% from the day prior. The stock remains around 1.75 a share.\nYOU MAY ALSO LIKE:\nThe Four Pillars Of The IBD Methodology\nRisk Management In The Stock Market: How Much Money To Invest\nIBD Live: Learn And Analyze Growth Stocks With The Pros\nGet Free IBD Newsletters: Market Prep | Tech Report | How To Invest","news_type":1},"isVote":1,"tweetType":1,"viewCount":9,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":308452813885640,"gmtCreate":1716327705420,"gmtModify":1716329540126,"author":{"id":"4115205500438802","authorId":"4115205500438802","name":"嗣舒","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4115205500438802","idStr":"4115205500438802"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/308452813885640","repostId":"2437446249","repostType":2,"repost":{"id":"2437446249","pubTimestamp":1716276750,"share":"https://ttm.financial/m/news/2437446249?lang=&edition=fundamental","pubTime":"2024-05-21 15:32","market":"us","language":"zh","title":"司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2437446249","media":"华尔街见闻","summary":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。","content":"<html><head></head><body><blockquote><p><strong>替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。</strong></p></blockquote><p>减肥药赛道竞争愈发激烈，<a href=\"https://laohu8.com/S/LLY\">礼来</a>穆峰达在华获批上市。</p><p>5月21日，国家药监局官网显示<strong>，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。</strong></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/77c56e4948bd5b7d48cfb79e511e5054\" tg-width=\"716\" tg-height=\"211\"/></p><p>替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，研究表明GIP可以减少食物摄入、增加能量消耗，从而减轻体重。<strong>当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。</strong></p><p><strong>值得一提的是，替尔泊肽能产生比有”减肥神药”之称的司美格鲁肽更好的减肥效果。</strong></p><p>相关研究数据表明表明，穆峰达5mg、10mg受试者体重平均降低7.8 kg、10.3 kg，司美格鲁肽1mg组平均降低6.2kg。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1cd6a793f8dc35a0cc9d5e0520c59d39\" tg-width=\"756\" tg-height=\"372\"/></p><p>去年，替尔泊肽获FDA批准用于慢性体重管理，以及体重相关合并症，如高血压、血脂异常、2型糖尿病、阻塞性睡眠呼吸暂停或心血管疾病，商品名为Zepbound。<strong>目前替尔泊肽减重适应症上市申请也获药监局受理，正在审评中。</strong></p><p>此外，减肥药大卖也在显著推升礼来业绩，Zepbound上市首季销售额超预期，完整季度就贡献5.17亿美元销售额，超出分析师预期的4.18亿美元。公司同时将全年营收指引上调20亿美元。</p><p>此前有行业分析师预测，替尔泊肽可能成为有史以来最畅销的药物之一，年销售额将突破500亿美元，将超过<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>的司美格鲁肽药物Ozempic和Wegovy。</p><p>目前礼来市值达7443亿美元，高于标普成分股中的<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>、<a href=\"https://laohu8.com/S/WMT\">沃尔玛</a>，为全球市值最高的药企。</p></body></html>","source":"wallstreetcn_hot_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-21 15:32 北京时间 <a href=https://wallstreetcn.com/articles/3715379><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3715379\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/83f07867b8f6f3f3fcb868d0fc0fa6be","relate_stocks":{"LLY":"礼来"},"source_url":"https://wallstreetcn.com/articles/3715379","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2437446249","content_text":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，研究表明GIP可以减少食物摄入、增加能量消耗，从而减轻体重。当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。值得一提的是，替尔泊肽能产生比有”减肥神药”之称的司美格鲁肽更好的减肥效果。相关研究数据表明表明，穆峰达5mg、10mg受试者体重平均降低7.8 kg、10.3 kg，司美格鲁肽1mg组平均降低6.2kg。去年，替尔泊肽获FDA批准用于慢性体重管理，以及体重相关合并症，如高血压、血脂异常、2型糖尿病、阻塞性睡眠呼吸暂停或心血管疾病，商品名为Zepbound。目前替尔泊肽减重适应症上市申请也获药监局受理，正在审评中。此外，减肥药大卖也在显著推升礼来业绩，Zepbound上市首季销售额超预期，完整季度就贡献5.17亿美元销售额，超出分析师预期的4.18亿美元。公司同时将全年营收指引上调20亿美元。此前有行业分析师预测，替尔泊肽可能成为有史以来最畅销的药物之一，年销售额将突破500亿美元，将超过诺和诺德的司美格鲁肽药物Ozempic和Wegovy。目前礼来市值达7443亿美元，高于标普成分股中的特斯拉、沃尔玛，为全球市值最高的药企。","news_type":1},"isVote":1,"tweetType":1,"viewCount":3,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":359181164835000,"gmtCreate":1728698717312,"gmtModify":1728698869527,"author":{"id":"4115205500438802","authorId":"4115205500438802","name":"嗣舒","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4115205500438802","authorIdStr":"4115205500438802"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/359181164835000","repostId":"2474093237","repostType":2,"repost":{"id":"2474093237","pubTimestamp":1728648005,"share":"https://ttm.financial/m/news/2474093237?lang=&edition=fundamental","pubTime":"2024-10-11 20:00","market":"sg","language":"en","title":"How To Invest: Biotechs Can Make Huge Gains But Have Unique Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2474093237","media":"Blockhead","summary":"In some cases, biotechs go public without having even a single product on the market.","content":"<html><body><div>\n<p>There are plenty of great growth stocks within IBD's biotechnology industry group. Investors have heard legendary stories of stocks like Genentech running up 300% in the 1980s or <strong>Amgen</strong> (AMGN) rocketing 600% in the early 1990s.</p>\n<p>When the gains look this good, what is keeping this from being the No. 1 industry group in every market cycle? Trouble is, biotech stocks have some unique risks that make them particularly volatile and often harder to trade.</p>\n<span>\n<span>\n<span jw-video-key=\"FczkHzgb\" vid-authors=\"RACHEL FOX\" vid-cat=\"Investor's Corner\" vid-date=\"09/26/2024\" vid-date-tmsp=\"1727347777\" vid-dom-id=\"9413049-67091849b73b3\" vid-id=\"9413049\" vid-image=\"https://www.investors.com/wp-content/uploads/2024/09/FczkHzgb-640x360.jpg\" vid-name=\"How To Buy Stocks: IBD's Four Pillars Of Investing\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/FczkHzgb.m3u8\" vid-width=\"100\">\n<span>↑</span>\n<span>X</span>\n<span>\n<span></span>\n<div>\n<div>\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n</div>\n<div>\nSee All Videos\n</div>\n</div>\n</span>\n<span>\n<span>NOW PLAYING</span>\n<span>How To Buy Stocks: IBD's Four Pillars Of Investing</span>\n</span>\n</span>\n</span>\n</span>\n<p>In some cases, biotechs go public without having even a single product on the market, making them quite speculative investments.</p>\n<h2>The Risks Of Biotechs</h2>\n<p>The biotech industry is flush with stocks on the cutting edge of science whose aim is to eradicate disease, increase life expectancy and vastly improve quality of life. The time and resources that it takes to bring these drugs and treatments to fruition means most companies are only producing one or two drugs at a time. All your eggs are in one or two baskets.</p>\n<p>If something goes wrong with that product, look out. The floor collapses from underneath and the stock's price plummets, sometimes never to recover. Worst of all, you can't prepare for a bad drug trial or an FDA rejection. They don't occur on a schedule like earnings reports do.</p>\n<p>It's worth mentioning that this type of risk extends to others in the medical sector, such as the ethical drugs group, which is also subject to regulatory approval and the risks of drug trials.</p>\n<h2>How To Trade Biotech Stocks</h2>\n<p>There are a few things that investors can do to mitigate the risk of trading biotech stocks.</p>\n<p>One way is to go with exchange traded funds, which bundle dozens of stocks in the industry and can mitigate the risk of a single stock having a meltdown.</p>\n<p>Your two most liquid options are the SPDR S&P Biotech ETF (XBI) and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotech ETF (IBB). Investors with high conviction can even trade the double-weighted ProShares Ultra Nasdaq Biotech ETF (BIB) or triple-weighted Direxion S&P Biotech Bull (LABU).</p>\n<p>Be warned, the double- and triple-leveraged ETFs can be backbreakers, exacerbating your losses if the industry makes a steep downturn.</p>\n<p>A second tip: smart stock selection. Start with success and choose from leading stocks with a new or revolutionary product. The biggest winners in any industry are the ones who are changing the game, and the same is true of biotechs. Focus on companies with strong sales growth.</p>\n<p>Amgen changed patient care in chemotherapy. Syntex was the first company to submit a patent for a birth control pill. <strong>Moderna</strong> (MRNA) and <strong>BioNTech</strong> (BNTX) were huge winners in 2020 and 2021 because of Covid-19 vaccines.</p>\n<p>Another tip on stock selection: Avoid stocks once they reach Phase 3 trials. Wall Street prefers stocks with positive Phase 2 data. In Phase 3, as the sample size increases, so does the chance of encountering dangerous side effects. Larger sample sizes can also reveal a drop in statistically meaningful positive responses.</p>\n<h2>Novo Nordisk & HilleVax Lessons</h2>\n<p>Last July, <strong>Novo Nordisk</strong> (NVO) stock was acting just fine. Then the Netherlands government decided to not cover the company's Wegovy weight-loss drug under the country's basic insurance plan. The stock sold off for two days, sending it below the 50-day moving average.</p>\n<p>On Sept. 20, results from a trial of an experimental obesity pill were disappointing. The stock fell 5.5% and continued to trend lower.</p>\n<p><strong>HilleVax</strong> (HLVX) is a small-cap biotech developing novel vaccines. The stock was forming a base this year until some bad news came out on July 8. Its experimental norovirus vaccine failed trials. The stock plummeted to $1.64, falling nearly 90% from the day prior. The stock remains around 1.75 a share.</p>\n<p><strong>YOU MAY ALSO LIKE:</strong></p>\n<p>The Four Pillars Of The IBD Methodology</p>\n<p>Risk Management In The Stock Market: How Much Money To Invest</p>\n<p>IBD Live: Learn And Analyze Growth Stocks With The Pros</p>\n<p>Get Free IBD Newsletters: Market Prep | Tech Report | How To Invest</p>\n</div></body></html>","source":"investor_business_daily_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How To Invest: Biotechs Can Make Huge Gains But Have Unique Risks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow To Invest: Biotechs Can Make Huge Gains But Have Unique Risks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 20:00 GMT+8 <a href=https://www.investors.com/how-to-invest/investors-corner/how-to-invest-biotech-stock-risks/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There are plenty of great growth stocks within IBD's biotechnology industry group. Investors have heard legendary stories of stocks like Genentech running up 300% in the 1980s or Amgen (AMGN) ...</p>\n\n<a href=\"https://www.investors.com/how-to-invest/investors-corner/how-to-invest-biotech-stock-risks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://www.investors.com/wp-content/uploads/2017/11/stock-biotech-05-adobe-150x150.jpg","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","IBB":"生物科技指数ETF-iShares Nasdaq","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4501":"段永平概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","NVO.AU":"NOVO RESOURCES CORP-CDI","LABU":"三倍做多标普生物-Direxion","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","AMGN":"安进","BK7104":"黄金","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4551":"寇图资本持仓","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BNTX":"BioNTech SE","BK4581":"高盛持仓","FDN":"First Trust Dow Jones Internet I","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","HLVX":"HilleVax, Inc.","MRNA":"Moderna, Inc.","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BIB":"Ultra纳斯达克生物科","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","BK4548":"巴美列捷福持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4532":"文艺复兴科技持仓","XBI":"SPDR S&P Biotech ETF","NVO":"诺和诺德"},"source_url":"https://www.investors.com/how-to-invest/investors-corner/how-to-invest-biotech-stock-risks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2474093237","content_text":"There are plenty of great growth stocks within IBD's biotechnology industry group. Investors have heard legendary stories of stocks like Genentech running up 300% in the 1980s or Amgen (AMGN) rocketing 600% in the early 1990s.\nWhen the gains look this good, what is keeping this from being the No. 1 industry group in every market cycle? Trouble is, biotech stocks have some unique risks that make them particularly volatile and often harder to trade.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n\n\n\n\nIn some cases, biotechs go public without having even a single product on the market, making them quite speculative investments.\nThe Risks Of Biotechs\nThe biotech industry is flush with stocks on the cutting edge of science whose aim is to eradicate disease, increase life expectancy and vastly improve quality of life. The time and resources that it takes to bring these drugs and treatments to fruition means most companies are only producing one or two drugs at a time. All your eggs are in one or two baskets.\nIf something goes wrong with that product, look out. The floor collapses from underneath and the stock's price plummets, sometimes never to recover. Worst of all, you can't prepare for a bad drug trial or an FDA rejection. They don't occur on a schedule like earnings reports do.\nIt's worth mentioning that this type of risk extends to others in the medical sector, such as the ethical drugs group, which is also subject to regulatory approval and the risks of drug trials.\nHow To Trade Biotech Stocks\nThere are a few things that investors can do to mitigate the risk of trading biotech stocks.\nOne way is to go with exchange traded funds, which bundle dozens of stocks in the industry and can mitigate the risk of a single stock having a meltdown.\nYour two most liquid options are the SPDR S&P Biotech ETF (XBI) and the iShares Biotech ETF (IBB). Investors with high conviction can even trade the double-weighted ProShares Ultra Nasdaq Biotech ETF (BIB) or triple-weighted Direxion S&P Biotech Bull (LABU).\nBe warned, the double- and triple-leveraged ETFs can be backbreakers, exacerbating your losses if the industry makes a steep downturn.\nA second tip: smart stock selection. Start with success and choose from leading stocks with a new or revolutionary product. The biggest winners in any industry are the ones who are changing the game, and the same is true of biotechs. Focus on companies with strong sales growth.\nAmgen changed patient care in chemotherapy. Syntex was the first company to submit a patent for a birth control pill. Moderna (MRNA) and BioNTech (BNTX) were huge winners in 2020 and 2021 because of Covid-19 vaccines.\nAnother tip on stock selection: Avoid stocks once they reach Phase 3 trials. Wall Street prefers stocks with positive Phase 2 data. In Phase 3, as the sample size increases, so does the chance of encountering dangerous side effects. Larger sample sizes can also reveal a drop in statistically meaningful positive responses.\nNovo Nordisk & HilleVax Lessons\nLast July, Novo Nordisk (NVO) stock was acting just fine. Then the Netherlands government decided to not cover the company's Wegovy weight-loss drug under the country's basic insurance plan. The stock sold off for two days, sending it below the 50-day moving average.\nOn Sept. 20, results from a trial of an experimental obesity pill were disappointing. The stock fell 5.5% and continued to trend lower.\nHilleVax (HLVX) is a small-cap biotech developing novel vaccines. The stock was forming a base this year until some bad news came out on July 8. Its experimental norovirus vaccine failed trials. The stock plummeted to $1.64, falling nearly 90% from the day prior. The stock remains around 1.75 a share.\nYOU MAY ALSO LIKE:\nThe Four Pillars Of The IBD Methodology\nRisk Management In The Stock Market: How Much Money To Invest\nIBD Live: Learn And Analyze Growth Stocks With The Pros\nGet Free IBD Newsletters: Market Prep | Tech Report | How To Invest","news_type":1},"isVote":1,"tweetType":1,"viewCount":9,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":308452813885640,"gmtCreate":1716327705420,"gmtModify":1716329540126,"author":{"id":"4115205500438802","authorId":"4115205500438802","name":"嗣舒","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4115205500438802","authorIdStr":"4115205500438802"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/308452813885640","repostId":"2437446249","repostType":2,"repost":{"id":"2437446249","pubTimestamp":1716276750,"share":"https://ttm.financial/m/news/2437446249?lang=&edition=fundamental","pubTime":"2024-05-21 15:32","market":"us","language":"zh","title":"司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2437446249","media":"华尔街见闻","summary":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。","content":"<html><head></head><body><blockquote><p><strong>替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。</strong></p></blockquote><p>减肥药赛道竞争愈发激烈，<a href=\"https://laohu8.com/S/LLY\">礼来</a>穆峰达在华获批上市。</p><p>5月21日，国家药监局官网显示<strong>，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。</strong></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/77c56e4948bd5b7d48cfb79e511e5054\" tg-width=\"716\" tg-height=\"211\"/></p><p>替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，研究表明GIP可以减少食物摄入、增加能量消耗，从而减轻体重。<strong>当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。</strong></p><p><strong>值得一提的是，替尔泊肽能产生比有”减肥神药”之称的司美格鲁肽更好的减肥效果。</strong></p><p>相关研究数据表明表明，穆峰达5mg、10mg受试者体重平均降低7.8 kg、10.3 kg，司美格鲁肽1mg组平均降低6.2kg。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1cd6a793f8dc35a0cc9d5e0520c59d39\" tg-width=\"756\" tg-height=\"372\"/></p><p>去年，替尔泊肽获FDA批准用于慢性体重管理，以及体重相关合并症，如高血压、血脂异常、2型糖尿病、阻塞性睡眠呼吸暂停或心血管疾病，商品名为Zepbound。<strong>目前替尔泊肽减重适应症上市申请也获药监局受理，正在审评中。</strong></p><p>此外，减肥药大卖也在显著推升礼来业绩，Zepbound上市首季销售额超预期，完整季度就贡献5.17亿美元销售额，超出分析师预期的4.18亿美元。公司同时将全年营收指引上调20亿美元。</p><p>此前有行业分析师预测，替尔泊肽可能成为有史以来最畅销的药物之一，年销售额将突破500亿美元，将超过<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>的司美格鲁肽药物Ozempic和Wegovy。</p><p>目前礼来市值达7443亿美元，高于标普成分股中的<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>、<a href=\"https://laohu8.com/S/WMT\">沃尔玛</a>，为全球市值最高的药企。</p></body></html>","source":"wallstreetcn_hot_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n司美格鲁肽“升级版”来了！礼来替尔泊肽注射液在华获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-21 15:32 北京时间 <a href=https://wallstreetcn.com/articles/3715379><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3715379\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/83f07867b8f6f3f3fcb868d0fc0fa6be","relate_stocks":{"LLY":"礼来"},"source_url":"https://wallstreetcn.com/articles/3715379","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2437446249","content_text":"替尔泊肽比司美格鲁肽减肥效果更好，当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。减肥药赛道竞争愈发激烈，礼来穆峰达在华获批上市。5月21日，国家药监局官网显示，礼来穆峰达（替尔泊肽注射液）获得国家药品监督管理局（NMPA）批准，用以改善成人2型糖尿病患者的血糖控制。替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。GLP-1和GIP是两种天然的肠促胰素，研究表明GIP可以减少食物摄入、增加能量消耗，从而减轻体重。当GIP与GLP-1受体激动剂联合使用时，可能会对患者血糖和体重产生更大的影响。值得一提的是，替尔泊肽能产生比有”减肥神药”之称的司美格鲁肽更好的减肥效果。相关研究数据表明表明，穆峰达5mg、10mg受试者体重平均降低7.8 kg、10.3 kg，司美格鲁肽1mg组平均降低6.2kg。去年，替尔泊肽获FDA批准用于慢性体重管理，以及体重相关合并症，如高血压、血脂异常、2型糖尿病、阻塞性睡眠呼吸暂停或心血管疾病，商品名为Zepbound。目前替尔泊肽减重适应症上市申请也获药监局受理，正在审评中。此外，减肥药大卖也在显著推升礼来业绩，Zepbound上市首季销售额超预期，完整季度就贡献5.17亿美元销售额，超出分析师预期的4.18亿美元。公司同时将全年营收指引上调20亿美元。此前有行业分析师预测，替尔泊肽可能成为有史以来最畅销的药物之一，年销售额将突破500亿美元，将超过诺和诺德的司美格鲁肽药物Ozempic和Wegovy。目前礼来市值达7443亿美元，高于标普成分股中的特斯拉、沃尔玛，为全球市值最高的药企。","news_type":1},"isVote":1,"tweetType":1,"viewCount":3,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
